ArticleFrontiers in immunology2026
Peripheral immune cell subsets as potential predictors of benefit from immune checkpoint blockade therapy in small cell lung cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell lung cancer (SCLC) is a lethal neoplasia. Chemotherapy (Ct) plus immune checkpoint blockade therapy (ICBt) is now the standard of care although limited survival benefit. Lack of biomarkers of response leads to suboptimal patient selection, distorting results of clinical trials. Deciphering the ICBt-driven peripheral immune events may recognize those patients who benefit the most. Here, we characterize early peripheral immune kinetics in SCLC patients treated with Ct + ICBt with improved survival. Methods: SCLC patients from 8 centers were prospectively recruited into 3 cohorts. Cohort 1 (N = 24) include patients treated with Ct. Cohort 2 (N = 37) comprise patients treated with Ct + anti-CTLA-4, and cohort 3 (N = 20) patients treated with Ct + anti-PD-1/PD-L1. Peripheral blood mononuclear cells (PBMCs) were obtained prior to treatment initiation and 3-4 weeks after (before cycle 2). Variation in proliferation, senescence, adhesion, immunosuppression, and checkpoints markers was assessed by Fluorescence-Activated Cell Sorting (FACS). Kaplan-Meier and log-rank test were used for survival analysis. MaxStat was used to calculate cut points. A p-value <0.05 was considered statistically significant. Results: We found 6 independent cellular subsets whose modulation shortly after the start of ICBt identify patients with improved survival. An increase in CD8+CD103+Ki67+ cells identify survival benefit in cohorts 1 and 3 (p=0.043; 0.0033). In ICBt cohorts 2 and 3, an upregulation of Ki67 in total CD4+ (p=0.012; 0.0027) and CD4+PD-1+ T cells (p=0.026; 0.027), predicted longer survival, while a downregulation of CD4+ICOS+ T cells (p=0.025; 0.011) identified survival benefit in these same ICBt cohorts. Expansion of Ki67+ and ICOS+ (p=0.0024; 0.0074) CD8+ T cells was also observed in CD8+ T cells from long survivors exclusively from cohort 2. Conclusions: This study provides one of the few longitudinal assessments of peripheral immune dynamics in SCLC patients receiving ICBt, suggesting that early on-treatment changes, evaluated relative to each patient's own baseline levels, may provide greater predictive value than single-timepoint inter-patient comparisons.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.